Want to see AUTL full AI Analyst Report?
AUTL Stock Chart & Stats
$2.36
-$0.07(-4.61%)
At close: 4:00 PM EDT
$2.36
-$0.07(-4.61%)
Day’s Range― - ―
52-Week Range$1.18 - $2.58
Previous CloseN/A
Volume717.00K
Average Volume (3M)2.80M
Market Cap
$596.19M
Enterprise Value$590.54
Total Cash (Recent Filing)$201.63M
Total Debt (Recent Filing)$83.51M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Oct 29, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding266,162,540
10 Day Avg. Volume1,556,783
30 Day Avg. Volume2,801,638
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.97
Price to Sales (P/S)7.01
P/FCF Ratio-1.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$8.16Price Target Upside245.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$149.40M
Bulls Say, Bears Say
Bulls Say
Accelerating AUCATZYL Commercial GrowthRapid product revenue growth and the higher full-year outlook indicate strengthening adoption of AUCATZYL. Sustained commercial traction could improve operating leverage and gradually shift Autolus toward a more durable product-led revenue model.
Improving Gross Margins And Manufacturing EconomicsThe margin inflection, supported by higher volumes and Nucleus facility production, suggests manufacturing efficiency is improving. Reaching the targeted mature margin range would strengthen contribution economics and reduce the funding burden of commercialization.
Broader Treatment-center Reach And Pipeline OptionalityA larger treatment-center network expands patient access and supports repeatable commercial execution. Meanwhile, programs such as AUTO8, BOBCAT, CATULUS and LUMINA provide longer-term product and indication optionality beyond the current lead therapy.
Bears Say
Persistent Losses And Substantial Cash BurnAutolus remains dependent on external funding while operating cash outflows are substantial. Unless revenue growth and gross-margin gains translate into stronger operating leverage, continued losses could consume liquidity and create recurring financing needs.
Financing Depends On Milestones And Adds Financial ObligationsMilestone-linked financing makes part of the expected liquidity runway dependent on execution against revenue targets. Secured obligations, floating interest costs and potential warrant issuance may constrain flexibility and increase shareholder dilution risk.
High Commercialization And Development Cost BaseAutolus is investing heavily in commercial infrastructure and its clinical pipeline while still operating at a loss. These costs may support future growth, but they also delay breakeven and raise execution risk if adoption or trial outcomes fall short.
Autolus Therapeutics News
AUTL FAQ
What was Autolus Therapeutics Plc’s price range in the past 12 months?
Autolus Therapeutics Plc lowest stock price was $1.18 and its highest was $2.58 in the past 12 months.
What is Autolus Therapeutics Plc’s market cap?
Autolus Therapeutics Plc’s market cap is $596.19M.
When is Autolus Therapeutics Plc’s upcoming earnings report date?
Autolus Therapeutics Plc’s upcoming earnings report date is Oct 29, 2026 which is in 52 days.
How were Autolus Therapeutics Plc’s earnings last quarter?
Autolus Therapeutics Plc released its earnings results on Aug 11, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.194 by $0.044.
Is Autolus Therapeutics Plc overvalued?
According to Wall Street analysts Autolus Therapeutics Plc’s price is currently Undervalued.
Does Autolus Therapeutics Plc pay dividends?
Autolus Therapeutics Plc does not currently pay dividends.
What is Autolus Therapeutics Plc’s EPS estimate?
Autolus Therapeutics Plc’s EPS estimate is -0.16.
How many shares outstanding does Autolus Therapeutics Plc have?
Autolus Therapeutics Plc has 266,162,540 shares outstanding.
What happened to Autolus Therapeutics Plc’s price movement after its last earnings report?
Autolus Therapeutics Plc reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.194. Following the earnings report the stock price went up 12.56%.
Which hedge fund is a major shareholder of Autolus Therapeutics Plc?
Currently, no hedge funds are holding shares in AUTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Autolus Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.16 (245.76% Upside)
$8.16 (245.76% Upside)
Blogger Sentiment
Bullish
AUTL Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $15.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
54.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Autolus Therapeutics Plc
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
AUTL Company Deck
AUTL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong commercial momentum for AUCATZYL with substantial QoQ and YoY revenue growth, a material gross margin inflection to 55%, expanding treatment center footprint (80+ centers) and multiple near-term clinical data catalysts. Financially, operating and net losses narrowed and the company secured a strategic credit facility that, combined with revenue expectations, extends cash runway into mid-2028. Offsetting risks highlighted include continued quarterly losses, higher SG&A related to commercialization and one-time charges, sustained R&D burn, some seasonality/visibility concerns, and contingent tranches of financing tied to milestones. On balance, the positive commercial execution, margin improvement, and funded runway outweigh the remaining operational and financing risks described on the call.View all AUTL earnings summariesAUTL Stock 12 Month Forecast
Average Price Target
$8.16
▲(245.76% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
<0.01% Insiders
0.36% Mutual Funds
39.76% Other Institutional Investors
59.00% Public Companies and
Individual Investors